We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bacterial Growth Assay Predicts COVID-19 Severity From Plasma

By LabMedica International staff writers
Posted on 14 Jul 2026

COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. More...

Early differentiation between patients likely to remain mild and those at risk of severe progression is vital for care pathways. Biological samples contain multiplexed chemical signals that may encode this prognostic information. New findings demonstrate that growth responses of Escherichia coli to patient plasma can distinguish mild from severe COVID-19.

INRAE, in collaboration with Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA, describes an approach that uses Escherichia coli (E. coli) as a living bacterial reservoir computer. Without genetic modification, the bacterium is placed in direct contact with plasma from patients with COVID-19. It adapts its metabolism and growth to the plasma’s chemical composition, generating a growth curve that reflects the detected signals.

The resulting growth curve is measured and treated as an information-processing output. In clinical samples, this readout was used to classify whether a patient was likely to develop mild or severe COVID-19. For additional computational tasks, researchers translated problems into defined nutrient mixtures that elicited analogous growth-based responses. Notably, the bacterium performed tasks typically assigned to machine-learning algorithms without prior training.

The research was published in Cell Systems and coordinated by INRAE, with participation from Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA. The authors indicate that genetically unmodified living organisms can convert the complexity of a sample into usable information. This approach could lead to simple, affordable diagnostic and prognostic tools that can be deployed in settings with limited technical resources. 

The team plans to explore additional applications, including monitoring environmental samples such as urban wastewater and analyzing other types of clinical specimens. More broadly, the work highlights the potential of living systems as platforms for information processing and sensing.

Related Links
INRAE 
Grenoble Alpes University Hospital


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.